Kishimoto Kazuya, Kaneko Satoshi, Ohmori Kenji, Tamura Tadafumi, Hasegawa Kazuhide
Pharmaceutical Research Center, Kyowa Hakko Kogyo Co, Ltd, Sunto-gun, Shizuoka, Japan.
Mediators Inflamm. 2006;2006(1):42726. doi: 10.1155/MI/2006/42726.
Olopatadine hydrochloride (olopatadine) is an antiallergic drug with histamine H(1) receptor antagonistic activity. Recently, olopatadine has been shown to bind to S100A12 which is a member of the S100 family of calcium-binding proteins, and exerts multiple proinflammatory activities including chemotaxis for monocytes and neutrophils. In this study, we examined the possibility that the interaction of olopatadine with S100A12 inhibits the proinflammatory effects of S100A12. Pretreatment of olopatadine with S100A12 reduced migration of THP-1, a monocyte cell line, induced by S100A12 alone, but did not affect recombinant human regulated upon activation, normal T cell expressed and secreted (RANTES)-induced migration. Amlexanox, which also binds to S100A12, inhibited the THP-1 migration induced by S100A12. However, ketotifen, another histamine H(1) receptor antagonist, had little effect on the activity of S100A12. These results suggest that olopatadine has a new mechanism of action, that is, suppression of the function of S100A12, in addition to histamine H(1) receptor antagonistic activity.
盐酸奥洛他定是一种具有组胺H(1)受体拮抗活性的抗过敏药物。最近研究表明,奥洛他定可与S100A12结合,S100A12是钙结合蛋白S100家族的一员,奥洛他定可发挥多种促炎活性,包括对单核细胞和中性粒细胞的趋化作用。在本研究中,我们探讨了奥洛他定与S100A12相互作用抑制S100A12促炎作用的可能性。用S100A12预处理奥洛他定可减少单独由S100A12诱导的单核细胞系THP-1的迁移,但不影响重组人活化调节正常T细胞表达和分泌趋化因子(RANTES)诱导的迁移。同样与S100A12结合的氨来呫诺可抑制S100A12诱导的THP-1迁移。然而,另一种组胺H(1)受体拮抗剂酮替芬对S100A12的活性几乎没有影响。这些结果表明,奥洛他定除具有组胺H(1)受体拮抗活性外,还具有一种新的作用机制,即抑制S100A12的功能。